Arthneeti

Mangalam Drugs and Organics Q2 FY27 Share Price & Earnings Call Analysis

₹28.80-6.01% today
Market cap
₹46 Cr
ROE
-34.80%
Price to sales
0.19
Debt to equity
1.09
52W high / low
₹63.8 / ₹23.8
Sales growth (5Y)
-9.39%
EBITDA margin
-3.82%
Net profit margin
-18.89%
Promoter holding
35.65%
Sales (last year)
₹232 Cr

Incorporated in 1977, Mangalam Drugs & Organics Ltd manufactures Active Pharmaceutical Ingredients and Intermediates.[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Mangalam Drugs rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹18,347 Cr—
440%+Flat₹8,418 Cr32.3
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Mangalam Drugs.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Mangalam Drugs

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Mangalam Drugs

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +50.31%50.31%50.31%50.30%50.30%50.30%50.30%50.30%35.64%35.65%35.65%35.65%
FIIs +0.10%0.26%0.21%0.11%0.11%0.47%0.53%0.11%0.13%0.32%0.11%0.11%
Public +49.59%49.42%49.47%49.58%49.58%49.23%49.16%49.57%64.22%64.03%64.24%64.24%
No. of Shareholders18,61019,17319,31219,50819,67919,69719,72819,88121,22725,14024,46523,991

Financials of Mangalam Drugs

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +81.5697.34102.2476.5379.9488.7172.7857.2149.5458.3867.2957.1279.39
YoY Sales growth-24.71%+53.73%+12.22%-12.50%-1.99%-8.87%-28.81%-25.25%-38.03%-34.19%-7.54%-0.16%+60.25%
Expenses +79.3790.3690.5468.3471.2579.9462.8861.8652.3759.9672.6556.2280.64
Operating Profit2.196.9811.708.198.698.779.90-4.65-2.83-1.58-5.360.90-1.25
OPM %2.69%7.17%11.44%10.70%10.87%9.89%13.60%-8.13%-5.71%-2.71%-7.97%1.58%-1.57%
Other Income +0.030.000.050.020.140.130.470.140.030.220.090.110.17
Interest3.243.313.953.753.673.494.034.045.034.053.083.683.89
Depreciation3.733.623.863.873.973.934.614.384.534.374.563.994.02
Profit before tax-4.750.053.940.591.191.481.73-12.93-12.36-9.78-12.91-6.66-8.99
Tax %-25.05%-920.00%9.90%-355.93%-125.21%5.41%90.75%6.19%-41.42%0.00%1.16%13.36%-19.80%
Net Profit +-3.560.503.552.682.691.400.15-13.73-7.25-9.78-13.06-7.55-7.21
EPS in Rs-2.250.322.241.691.700.880.09-8.67-4.58-6.18-8.25-4.77-4.56

Financials of Mangalam Drugs

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +221295299269228282380451372369318232262
Sales growth+80%+34%+1%-10%-15%+24%+35%+19%-17%-1%-14%-27%-2%
Expenses +200257252222218259327402347351282247269
Operating Profit2038474710245349261736-15-7
OPM %9%13%16%17%4.3%8%14%11%7%4.7%11%-6%-2.8%
Other Income +00-01015000111
Interest10910129109111314151615
Depreciation4457789101115161817
Profit before tax6243129-6640282-115-48-38
Tax %-2%33%29%32%40%-32%29%29%43%-18%-39%-9%
Net Profit +6162220-8828201-97-44-38
EPS in Rs4.6611.1514.0812.57-5.075.2117.6712.420.80-5.724.37-27.68-23.76
Dividend Payout %0%0%0%4%0%0%0%0%0%0%0%0%

Financials of Mangalam Drugs

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital13141616161616161616161616
Reserves1647708880881151351361271338772
Borrowings +7860666965527088891079611390
Other Liabilities +633838545075649011710811492113
Total Liabilities170160190227211231264328358357359308292
Fixed Assets +535493102103101118135142147156148146
CWIP0500016698340
Investments0020000000000
Other Assets +11710095125107128140188206202201156146
Total Assets170160190227211231264328358357359308292

Financials of Mangalam Drugs

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +14224325223128263812434
Cash from Investing Activity +-4-11-39-16-9-7-31-27-22-18-19-12
Cash from Financing Activity +-10-11-3-9-11-2333-176-226
Net Cash Flow1-00-010-11-1-02-2
Free Cash Flow1011391224-4-216-623-8
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit69%68%107%66%223%129%69%70%148%71%121%-30%

Financials of Mangalam Drugs

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days733745612852523846284563
Inventory Days134856913217512185139200185303239
Days Payable128373882771066365139124199160
Cash Conversion Cycle798575111126677411210788148142
Working Capital Days2632193121102343381813-54
ROCE %16%29%31%25%2%11%27%18%6%1%8%-14%

Continue your research

What Mangalam Drugs's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Kilitch Drugs (Q2 FY27)

    14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • NGL Fine Chem (Q2 FY27)

    Consolidated: ₹15,870.73 lakhs . Key results statement takeaways from NGL Fine Chem Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Astrazeneca Phar (Q2 FY27)

    Year-on-year revenue growth for the quarter: Rs 7,291.0 million vs Rs 5,590.9 million, approximately 30.5% increase. Key results statement takeaways from Astraz

  • Cohance Lifesciences Ltd (Q2 FY27)

    Q2 FY27 revenue: INR 4,766 Mn, down 14.2% YoY (Page 8, 9) . Key investor presentation takeaways from Cohance Lifesciences Ltd's Q2 FY27 investor presentation —

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals